Clinical trials: HCV, HIV
Treatment of Hepatitis C
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA < 6 x106 IU/mL Duration of…
- Trial name
- NCT02480387
- Testing
- Ledipasvir/Sofosbuvir FDC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Peter J. Ruane, M.D., Inc.
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- EXPEDITION-2 (NCT02738138)
- Testing
- ABT-493 coformulated with ABT-530
- Volunteers
- 153 people
- Sponsor
- AbbVie
HIV Infections
Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)
The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs…
- Trial name
- ACCESS (NCT06730555)
- Testing
- ACCESS Intervention, Control Group
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections, HCV Infection
APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies
Human Immunodeficiency Virus (HIV), hepatitis C (HCV), and syphilis are sexually transmitted and blood borne infections (STBBI) that affect millions of people worldwide and rates are rising in Canada.
- Conditions
- HIV Infections, HCV Infection, Syphilis Infection
- Trial name
- NCT05534633
- Testing
- Choice of STBBI test(s)
- Where
- Canada
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Memorial University of Newfoundland
HIV Infections
DENTAL CARE OF PATIENTS LIVING WITH HIV
This study is perform to identify oral diseases of people living with HIV (PLWHIV) or co-infected with HBV or HCV.
- Trial name
- DENTA-VIH (NCT05123547)
- Where
- France
- Volunteers
- 112 people
- Sponsor
- University Hospital, Clermont-Ferrand
HIV
Quality of Care in French HIV Infected Patients
The objective of the Dataids cohort is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data on a large cohort of HIV infected patients seeking care in 15 HIV centers in France in order : 1.
- Trial name
- Dataids_PEC (NCT02898987)
- Where
- 39 sites in France, Guadeloupe and 1 more
- Volunteers
- 30,000 people
- Sponsor
- DatAids
Hepatitis C Virus Genotype-1
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects…
- Trial name
- NCT01479868
- Testing
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Janssen R&D Ireland
HIV, Hepatitis C
Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France
To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Tuberculosis
- Trial name
- STRADA (NCT02959684)
- Where
- 18 sites in France
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- University Paris 7 - Denis Diderot
HIV Infections, Hepatitis C
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected…
- Trial name
- NCT00008463
- Testing
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Where
- 24 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
Effects of Ribavirin on Zidovudine or Stavudine
The purpose of this study is to see how treatment of hepatitis C (HCV) patients with ribavirin (RBV) affects the anti-HIV drugs stavudine (d4T) or zidovudine (ZDV).
- Trial name
- NCT00021632
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus
This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection.
- Conditions
- Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, HIV Infections
- Trial name
- NCT00499434
- Where
- Brazil
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV Infections, Drug Use
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and…
- Conditions
- HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder
- Trial name
- INTEGRA (NCT04804072)
- Testing
- Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care
- Where
- 5 sites in United States
- Volunteers
- 447 people
- Sponsor
- HIV Prevention Trials Network
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
Compensated Cirrhosis
Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection…
- Trial name
- NCT03037151
- Testing
- Grazaoprevir/Elbasavir, Grazaoprevir/Elbasavir/RBV
- Where
- 2 sites in Thailand
- Volunteers
- 100 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis C, Chronic
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up…
- Trial name
- NCT02761629
- Testing
- Peg-Interferon Alpha-2A, Ribavirin
- Where
- 17 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche